New therapies for Parkinson's disease

Journal of Neurology

Volumn 248, Issue 5, 2001, Pages 357-362

  Djaldetti, Ruth ^a,b   Melamed, Eldad ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Levodopa; Parkinson's disease; Therapy

Indexed keywords

AMANTADINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; ONDANSETRON; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RILUZOLE; RISPERIDONE; ROPINIROLE;

BRAIN TRANSPLANTATION; CAUDATE NUCLEUS; CONFUSION; DELIRIUM; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; HUMAN; NEUROPROTECTION; ON OFF PHENOMENON; PALLIDOTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; REVIEW;

ADULT; AGE FACTORS; AGED; ANTIPARKINSON AGENTS; FETAL TISSUE TRANSPLANTATION; GENE THERAPY; HUMANS; LEVODOPA; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, DOPAMINE; SEVERITY OF ILLNESS INDEX;

EID: 0035016154     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150170174     Document Type: Review

References (42)

1. Koller WC, Hubble JP (1990) Levodopa therapy in Parkinson's disease. Neurology 40:40-47
2. Uitti RJ, Ahlskog JG, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC (1993) Levodopa therapy and survival in idiopathic Parkinson's disease: Olmstead County Project. Neurology 43:1918-1926
3. Chase TN (1998) Levodopa therapy. Consequences of the non-physiologic replacement of dopamine. Neurology 50:S17-S25
4. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann Neurol 32:804-812
5. Spencer JP, Jenner A, Aruoma OL, Marsden CD, Hallwell B (1994) Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative diseases. FEBS lett 353:246-250
6. Bedard PJ, Blanchet PJ, Levesque D, Soghomonian JJ, Grondin R, Morisette M, Goulet M, Calon F, Falardeau P, Gomez-Manzilla P, Doucet JP, Robertson GS, DiPaolo T (1998) Pathophysiology of L-dopa induced dyskinesias. Mov Disord 14:4-8
7. Calabresi P, Giacomini P, Centonze D, Bernardi G (2000) Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 47:S60-S68
8. Filion M (2000) Physiologic basis of dyskinesia. Ann Neurol 47:S35-S40
9. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 55:23-30
10. Parkinson study group (1997) Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA 278:125-130
11. Bressman SB, Shulman LM, Taner CM, Rajput AH, Shannon KM, Wright E (1999) Long-term safety and efficacy of pramipexole in early Parkinson's disease. Neurology 52:A261
12. Rascol O, Brooks DJ, Korczyn AD, De-Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with Parkinson's disease who are treated with ropinirole and levodopa. 056 Study Group. N Engl J Med 342:1484-1491
13. Montastruc JL, Rascol U, Senard JN (1999) Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 14:726-730
14. Weiner WJ (1999) The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord 14:716-724
15. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326
16. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R (1999) Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 22:273-276
17. Merims D, Ziv I, Djaldetti R, Melamed E (1999) Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet 353:1764-1765
18. Hutchinson W, Lozano AM (1999) Posteroventral medial pallidotomy in Parkinson's disease. J Neurol 246:II28-41
19. Ghika J, Ghika-Schmid F, Fankhauser H, Assal G, Vingerhoets F, Albanese A, Bogousslavsky J, Favre J (1999) Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: Neuropsychological and neurological side effects. Report of four cases and review of the literature. J Neurosurg 91:313-321
20. Fahn S (1982). Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Movements Disorders. Marsden CD, Fahn S, eds. London, Butterworth Scientific, 123-145
21. Melamed E, Bitton V, Zelig O (1986). Delayed onset of response to single doses of L-dopa therapy. Clin Neuropharmacol 9:182-188
22. Melamed E, Bitton V, Zelig O (1986) Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 36:100-103
23. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 24:366-371
24. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 24:372-378
25. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN (1994) Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanism. Ann Neurol 36:27-31
26. Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, Shoulson I (1988) Eratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian motility. Neurology 38:419-421
27. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 46:1051-1054
28. Pincus JH, Barry K (1987) Influence of dietary protein on motor fluctuations in Parkinson's disease. Arch Neurol 44:270-272
29. Djaldetti R, Melamed E (1998) Management of response fluctuations. Practical guidelines. Neurology 51:S36-S40.
30. Stibe CM, Lees AJ, Kempster PA, Stern GM (1998) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1:403-406
31. Follett KA (2000) The surgical treatment of Parkinson's disease. Annu Rev Med 51:135-147
32. Limousin P, Pollak P, Benabid A (1995) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91-95
33. Friedman JH, Factor SA (2000) Atypical psychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15:201-211
34. Zoldan J, Friedberg G, Livneh M, Melamed E (1995) Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45:1305-1308
35. Tabbal S, Fahn S, Frucht S (1998) Fetal tissue transplantation in Parkinson's disease. Curr Opin Neurol 11:341-349
36. Clarkson ED, Freed CR (1999) Development of fetal neural transplantation as a treatment for Parkinson's disease. Life Sci 65:2427-2437
37. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penny D, Fink JS, Isacson O (2000) Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54:1042-1050
38. Prasad KN, Cole WC, Hovland AR, Prasad KC, Nahreini P, Kumar B, Edwards-Prasad J, Andreatta CP (1999) Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr Opin Neurol 12:761-770
39. Drukarch B, van Muiswinkel FL (2000) Drug treatment of Parkinson's disease. Time for phase II. Biochem Pharmacol 59:1023-1031
40. Hirsch EC (2000) Glial cells and Parkinson's disease. J Neurol 247:II58-62
41. Tompkins MM, Basgall EJ, Zamrini E, Hill WD (1997) Apoptotic-like changes in Lewy - body-associated disorders and normal aging in substantia nigra neurons. Am J Pathol 150:119-131
42. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97:2875-2880